TY - JOUR
T1 - Management of recurrent nasopharyngeal carcinoma
T2 - current perspectives
AU - Perri, F
AU - Della Vittoria Scarpati, G
AU - Caponigro, F
AU - Ionna, F
AU - Longo, F
AU - Buonopane, S
AU - Muto, P
AU - Di Marzo, M
AU - Pisconti, S
AU - Solla, R
PY - 2019
Y1 - 2019
N2 - Nasopharyngeal carcinoma is a rare disease in Western countries. Nevertheless, its incidence in China, Singapore, and other Eastern countries reaches 20 cases per 100,000 people. Being an extremely chemo- and radiosensitive disease, upfront treatment often consists in the association of intensity-modulated radiation therapy and concurrent cisplatin. Unfortunately, about 20% of the patients suffer from a radioresistant disease which recurs after upfront therapy. For these patients, mainly available therapeutic options consist in systemic therapy, in particular poly-chemotherapy. In those showing a single locoregional recurrence, chemotherapy is not considered to be the preferred approach and other different strategies may be employed. Re-irradiation and surgery are strategies that are always used more often, albeit related to high risk of morbidity. Immunotherapy and targeted therapy, such as heavy ions-based re-irradiations, are experimental but very intriguing options.
AB - Nasopharyngeal carcinoma is a rare disease in Western countries. Nevertheless, its incidence in China, Singapore, and other Eastern countries reaches 20 cases per 100,000 people. Being an extremely chemo- and radiosensitive disease, upfront treatment often consists in the association of intensity-modulated radiation therapy and concurrent cisplatin. Unfortunately, about 20% of the patients suffer from a radioresistant disease which recurs after upfront therapy. For these patients, mainly available therapeutic options consist in systemic therapy, in particular poly-chemotherapy. In those showing a single locoregional recurrence, chemotherapy is not considered to be the preferred approach and other different strategies may be employed. Re-irradiation and surgery are strategies that are always used more often, albeit related to high risk of morbidity. Immunotherapy and targeted therapy, such as heavy ions-based re-irradiations, are experimental but very intriguing options.
U2 - 10.2147/OTT.S188148
DO - 10.2147/OTT.S188148
M3 - Review article
C2 - 30881013
VL - 12
SP - 1583
EP - 1591
JO - OncoTargets and Therapy
JF - OncoTargets and Therapy
SN - 1178-6930
ER -